Finoriq research workspace
Aura Biosciences, Inc. (AURA) SEC Filings & Filing Highlights
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to. Review AURA SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
- Company
- Aura Biosciences, Inc. (AURA)
- Ticker
- AURA
- Market Cap
- $704.4M
- Latest Price
- $6.81
- Industry
- Biotech & Pharma
Aura Biosciences, Inc. (AURA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Aura Biosciences, Inc. (AURA).
| Event | Form | Date |
|---|---|---|
| Appointment of New Director to the Board of Directors On July 3, 2026, the Board of Directors (...Appointment of New Director to the Board of Directors On July 3, 2026, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the... | 8-K5.02 | 2026-07-08 |
| On June 11, 2026, Aura Biosciences, Inc. held its 2026 Annual Meeting of Stockholders. The prop...On June 11, 2026, Aura Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The proposals... | 8-K5.07 | 2026-06-11 |
| Aura Biosciences Reports First Quarter 2026 Financial Results and Business HighlightsAura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights | 8-K8.01 | 2026-05-11 |
| Aura Biosciences Reports First Quarter 2026 Financial Results and Business HighlightsAura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights | 8-K2.02 | 2026-05-11 |
| Aura Biosciences, Inc.: Material agreementOn May 4, 2026, Aura Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink P... | 8-K1.01 | 2026-05-05 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.